| Vol. 13.04 – 4 February, 2021 |
| |
|
|
| Scientists identified a discrete population of CD39+PD-1+CD8+ T cells in primary tumors and in dormant metastasis, which is hardly found in aggressively metastasizing tumors. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Parental breast cancer cells and their endocrine-resistant derivatives were used. Derivatives with acquired resistance to palbociclib were generated from parental and estrogen-deprivation resistant MCF7 and T47D cells. [Clinical Cancer Research] |
|
|
|
| A high level of miR-211 could act as a brain metastatic prognostic marker in vivo. SOX11 and NGN2 were the downstream targets of miR-211 and negatively regulated miR-211-mediated TNBC brain metastasis in vitro and in vivo. [Oncogene] |
|
|
|
| In tamoxifen-resistant ESR1 breast cancer cells, NUPR1 depletion resulted in premature senescence in vitro and tumor suppression in vivo. [Cell Death & Disease] |
|
|
|
| Researchers evaluated if IMMUNEPOTENT CRP induced immunogenic cell death in breast cancer cells. [British Journal of Cancer] |
|
|
|
| Scientists found that poly-L-glutamic acid (PLE)-coated nanoparticles (NPs) bond to STAT3-transformed breast cancer cells with 50% greater efficiency than to non-transformed cells, and the heightened PLE-NP binding to TNBC cells was attenuated by STAT3 inhibition. [Molecular Cancer Therapeutics] |
|
|
|
| The authors report that Ras-GTPase activating SH3 domain-binding protein 1 (G3BP1) was upregulated and correlated with poor prognosis in breast cancer. [Acta Pharmacologica Sinica] |
|
|
|
| LINC00958 was markedly overexpressed in breast cancer (BC) tissue and cells, and LINC00958 upregulation promoted the tumor progression of BC cells. [Cell Death Discovery] |
|
|
|
| The authors report evaluation of mechanical properties of two breast cancer cells with different metastatic ability at the site of bone metastases, using quasi-static and dynamic nanoindentation methods. [Scientific Reports] |
|
|
|
| Investigators generated carboplatin-resistant TNBC MDA-MB-468 cell line and patient derived TNBC xenograft models. [Scientific Reports] |
|
|
|
|
| Scientists present a comprehensive review of the current applications and preclinical studies of various actively targeted nanoparticles for specific delivery of different chemotherapeutics agents used for the management of breast cancer. [Biomedicines] |
|
|
|
|
| Atossa Therapeutics, Inc. announced updated findings following 26 months of Expanded Access single-patient studies of Atossa’s Endoxifen. [Atossa Therapeutics, Inc.] |
|
|
|
|
|
|
|
| University of Nebraska Medical Center – Omaha, Nebraska, United States |
|
|
|
| KU Leuven – Leuven, Belgium |
|
|
|
| Gilead Sciences, Inc. – London, England, United Kingdom |
|
|
|
| Gilead Sciences, Inc. – Munich, Germany |
|
|
|
| Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
|